Differential Cardiometabolic Outcomes of Leuprolide Versus Spironolactone in Women With Polycystic Ovary Syndrome

    Myles Goliger, Michael Kozlov, Esther Auerbach, Jacob Givoni, Robert A. Adler, Jeffrey P. Weiss, Jason Lazar
    TLDR Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.
    A recent study compared the cardiometabolic outcomes of leuprolide versus spironolactone in women with polycystic ovary syndrome (PCOS). The results indicated that leuprolide therapy was associated with improved lipid profiles and better management of hypertension compared to spironolactone. These findings suggest that leuprolide may have a potential role in the broader metabolic management of PCOS.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results